Bibliografía del artículo
1. Hopkins HS, Gelenberg AJ. Treatment of bipolar disorder: how far have we come? Psychopharmacology Bulletin 30:27-38, 1994.
2. Schulman KI, Tohen M, Kutcher SP. Mood disorders across the life span. New York, USA: John Wiley & Sons, Inc. 1996.
3. Tohen M, Hennen J, Zarate CMJr et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry 157:220-228, 2000.
4. Regier DA, Farmer ME, Rae DS et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. Journal of the American Medical Association 264:2511-2518, 1990.
5. Feinman JA, Dunner DL. The effect of alcohol and substance abuse on the course of bipolar affective disorder. J Affect Disord 37:43-49, 1996.
6. Keck PE Jr, McElroy SL, Strakowski SM et al. Outcome and comorbidity in first-compared with multiple-episode mania. J Nervous and Mental Disease 183:320-324, 1995.
7. Pini S, Cassano GB, Simonini E et al. Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia. J Affect Disorder 42:145-153, 1997.
8. Chen YW, Dilsaver SC. Comorbidity for obsessive-compulsive disorder in bipolar and unipolar disorders. Psychiatry Res 59:57-64, 1995.
9. Ucok A, Karaveli D, Kundakci T et al. Comorbidity of personality disorder with bipolar mood disorders. Psychiatric Research 59:57-64, 1998.
10. Bowden CL, Krishnan AA. Pharmacotherapy for bipolar depression: an economic assessment. Expert Opinion Pharmacotherapy 5:1101-1107, 2004.
11. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Bipolar Disorder. Am J Psychiatry 151:1-36, 1994.
12. Sachs GS, Printz DJ, Kahn DA et al. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. McGraw-Hill Companies: A Postgraduate Medicine Special Report 2000.
13. Bowden CL. Lamotrigine in the treatment of bipolar disorder. Expert Opinion Pharmacother 10:1513-1519, 2002.
14. Calabrese JR, Bowden CL, Sachs GS et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 60:79-88, 1999.
15. Reviki DA, Paramore LC, Sommerville KW et al. Divalproex sodium versus olanzapine in the treatment of bipolar disorder: health related quality of life and medical cost outcomes. J Clin Psychiat 64:288-294, 2003.
16. Prien RF, Gelenberg AS. Alternatives to lithium for preventive treatment of bipolar disorder. Am J Psychiatry 146:840-848, 1989.
17. Bowden CL. Valproate. Bipolar Disorders 5:189-202, 2003.
18. Sharpe JK, Hills AP. Atypical antipsychotic weight gain: a major clinical challenge. Aust NZJ Psychiatry 37:705-709, 2003.
19. Perry A, Tarrier N, Morriss R et al. Randomized controlled clinical trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ 318:149-153, 1999.
20. Miklowitz DJ, George EL, Richards JA et al. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient managment of bipolar disorder. Arch Gen Psychiatry 60:904-912, 2003.
21. Frank E, Swartz H, Mallinger A et al. Adjunctive psychotherapy for bipolar disorder: Effect of changing treatment modality. J Abnorm Psychol 1089:579-587, 1999.
22. Colom F, Vieta E, Martinez-Aran A et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 60:402-407, 2003.
23. Bauer MS, Kirk GF, Gavin C et al. Determinant of functional outcome and health care costs in bipolar disorder: A high-intensity follow-up study. J Affec Disord 65:231-241, 2001.
24. Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry 60:392-400, 2003.
25. Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 64:1013-1024, 2003.
26. Gyulai L, Bowden CL, McElroy SL et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28:1374-1382, 2003.
27. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349:1436-1442, 1997.
28. Cooke RG, Robb JC, Young LT et al. Well-being and functioning in patients with bipolar disorder assessed using the MOS 20-item short form (SF-20). J Affec Disorder 39:93-97, 1996.
29. A state of the science report for the office of the Science Secretary for the US Department of Health, Education, and Welfare 1979.
30. Hirschfeld RMA, Calabrese J, Reed M et al. Impact of bipolar depression compared with unipolar depression. New Research Abstracts of the 156th American Psychiatric Association Annual Meeting. San Francisco, CA, USA 146, 2003.
31. Kupfer DJ, Frank E, Grochocinski VJ et al. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiat 63:120-125, 2002.
32. Kessler RC, Chiu WT, Demler O et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 62:617-627, 2005.
33. Lecrubier Y, Davis K, Harris S. Impact of depression and mania on quality of life in bipolar compared with unipolar depression and United Kingdom population norms. Euro Neuropsychopharmacol 12:S214, 2002.
34. Yatham LN, Lecrubier Y, Fieve RR et al. Quality of life in patients with bipolar I depression: data from 920 patients. Bipolar Disorder 6:379-385, 2004.
35. Hyman S, Chisholm D, Kessler R et al. Priorities related to mental, neurological, developmental and substance abuse. World Health Organization, 2006.
36. Wood SW. The economic burden of bipolar disease. J Clin Psychiatry 61:38-41, 2000.
37. Lfietime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other Axis I disorders. Biol Psychiatry 39:896-899, 1996.
38. Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry 56:617-626, 1999.
39. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry 59:530-537, 2002.
40. Keller MB, Lavori PW, Coryell W et al. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. JAMA 255:3138-3142, 1986.
41. Keller MB, Baker LA. Bipolar disorder: epidemiology, course, diagnosis, and treatment. Bull Menninger Clin 55:172-181, 1991.
42. Isometsa ET. Course, outcome, and suicide risk in bipolar disorder: A review. Psychaitria Fennica 24:113-124, 1993.
43. Dilsaver SC, Chen YW, Swan AC et al. Suicidality, panic disorder and psychosis in bipolar depression, depressive mania and pure-mania. Psychiatry Res 73:47-56, 1997.
44. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York: Oxford University Press, Inc., 1990.
45. Rapaport MH, Kennedy SH, Davis KH. Effects of lamotrigine on quality of life. Journal of the European College of Neuropsychopharmacology 12:S457, 2003.
46. Yatham LN, Davis KH, Khan A et al. Effect of lamotrigine on neurocognitive measures in patients with bipolar I disorder. Journal of the European College of Neuropsychopharmacology 13:S227, 2003.
47. Craig T, Bromet E, Jandorf L et al. Diagnosis, treatment, and six-month outcome status in first-admission psychosis. Ann Clin Psychiatry 9:89-97, 1997.
48. Gitlin M.J., Swendsen J, Heller TL et al. Relapse and impairment in bipolar disorder. Am J Psychiatry 152:1635-1640, 1995.
49. Solomon D, Ristow WR, Keller M et al. Serum lithium levels and psychosocial function in patients with bipolar I disorder. Am J Psychiatry 153:1301-1307, 1996.
50. Das Gupta R, Guest JF. Annual cost of bipolar disorder to UK society. Br J Psychiatry 180:227-233, 2002.
51. Stender M, Bryant-Comstock L, Phillips S. Medical resource use among patients treated for bipolar disorder: A retrospective, cross-sectional, descriptive analysis. Clin Ther 24:1668-1676, 2002.
52. Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatric Sciences 50:1303-1308, 1999.
53. Li J, McCombs JS, Stimmel GL. Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program. J Affec Disorders 71:131-139, 2002.
54. Begley CE, Annegers JF, Swann AC et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. PharmacoEconomics 19:483-495, 2001.
55. Keck PE, Nabulsi AA, Taylor JL et al. A pharmacoeconomic model of divalproex vs lithium in the acute and prophylactic treatment of bipolar I disorder. J Clin Psychiatry 57:213-222, 1996.
56. Steffens DC, Krushnan KRR. Decision model for the acute treatment of mania. Depression and Anxiety 4:289-293, 1997.
57. Davis KH, O'Leary M, Calvert N et al. Treatment and economic outcomes in patients with bipolar disorder. Neuropyschopharmacol 13:S457, 2003.
58. Chisholm D, van Ommeren M, Ayuso-Mateos JL et al. Cost-effectiveness of clinical interventions for reducing the global burden of bipolar diosrder. British Journal of Psychiatry 187:559-567, 2005.
59. Calvert NW, Burch SP, Fu AZ et al. The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. Journal of Managed Care Pharmacy 12:322-330, 2006.
60. Isojarvi JI, Laatikainen TJ, Knip M et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 39:579-584, 1996.
61. Baptista T, Teneud L, Contreras Q et al. Lithium and body weight gain. Pharmacopsychiatry 28:35-44, 1995.
62. Rattya T, Teneud L, Contreras Q et al. Early Hormonal changes during valproate or carbamazepine treatment: a 3 month study. Neurology 57:444, 2001.
63. Akiskal HS, Fuller MA, Hirschfeld RM et al. Reassessing carbamazepine in the treatment of bipolar disorder: clinical impliciatons of new data. CNS Spectrum 10S:1-11, 2005.
64. Isojarvi JI, Rattya J, Myllyla VV et al. Valproate, lamotrigine, and insulin-medicated risks in women with epilepsy. Ann Neurol 43:446-451, 1998.
65. Marcus SC, Olfson M, Pincus HA et al. Therapeutic drug monitoring of mood stabilizers in Medicaid patients with bipolar disorder. Am J Psychiatry 156:1014-1018, 1999.
66. Osby U, Brandt L, Correia N et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 58:844-850, 2001.
67. Kilbourne AM, Cornelius JR, Han X et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disorder 6:368-373, 2004.
68. Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disorder 4:398-405, 2002.
69. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness - 1991. Soc Psychiatry Psychiatr Epidemiol 30:213-219, 1995.